Monday, August 07, 2017 3:39:38 PM
So at this moment in time, based on P/S ratio, we are 7% undervalued. But hold the phone, this MC doesn’t price in any expectations of future potential of drugs in clinical development. We can take look at this 2 ways.
Let’s look at it, unrealistically, and say SPPI management is aware that their SP doesn’t value the future potential of their promising drugs in Phase 3 (Rolontis, Poziotinib, and Qapzola). And they cut off all future development of these drugs. That means their R&D expenses will go to nearly zero. R&D this Q was 15M, multiply that by 4 quarters and you get 60M. How would you value this 60M/ yr of pure profit? For the sake of argument let’s multiple it by the 5.86 P/S ratio. That’s another 352M in MC, if you divide that by the weighted average # of shares, or 78.6M, you get another $4.50 that the SP should go up. As I said this is unrealistic but you get the idea.
So what happens if we price in the future value of Rolontis and Poziotinib. Several months ago, I posted that EvaluatePharma forecast sales of CHS-1701 (biosimilar to Neulasta) are to reach $648m by 2022. As a FYI, CHS-1701 got a CRL, so won’t be on the market till next year or later. For the sake of argument, let say Rolontis, will capture the same or 648M. A couple of posts ago, I provided some thoughts on Poziotinib, just in Exon 20 insertion mutations in NSCLC can easily attain 500M in sales. So between these 2 drugs, $1150M in additional sales by some future date. If you multiple $1150M plus the existing 129M in sales that’s a total of $1279M in sales and you multiple that by a P/S ratio of 6 you get 7.6B in MC. Let’s say by then that the # of shares goes up to 100M then 1270M *6/100M sh = 77$.
So to answer your Q, at this point in time, a realistic near future stock price should be at least $14.20 ($9.70 + 4.50 if did w/o R&D) and less than the future value of $77 once Rolontis and Poziotinib get approved. This is all IMHO and as you know the future price will be dictated by the potential of poziotinib in other cancers like Breast cancer, or potential CRLs or disapprovals, potential licensing agreements etc. Hope this helps.
http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM